Mark W. Grinstaff, PhD

Professor, Chemistry

Mark Grinstaff
590 Commonwealth Ave


Mark W. Grinstaff is a Distinguished Professor of Translational Research, Biomedical Engineering, Chemistry, Materials Science and Engineering, and Medicine as well as the Director of the NIH T32 Program in Biomaterials and the Director of the Nanotechnology Innovation Center at Boston University.

Mark received his Ph.D. from the University of Illinois under the mentorship of Professor Kenneth S. Suslick and was an NIH postdoctoral fellow at the California Institute of Technology with Professor Harry B. Gray. Mark’s awards include the ACS Nobel Laureate Signature Award, NSF Career Award, Pew Scholar in the Biomedical Sciences, Camille Dreyfus Teacher- Scholar, Alfred P. Sloan Research Fellowship, the Edward M. Kennedy Award for Health Care Innovation, and a Founding Fellow of the National Academy of Inventors. He is an author or co-author on more than 225 peer-reviewed manuscripts, given more than 300 oral presentations, and an inventor or co- inventor on more than 200 issued patents or pending applications. His students and fellows have given more than 125 oral presentations and 350 posters at national and international meetings.

Mark’s current research activities involve the synthesis of new macromolecules and biomaterials, self-assembly chemistry, imaging contrast agents, drug delivery, and wound repair. His group pursues highly interdisciplinary research in the areas of biomedical engineering and macromolecular chemistry. The major goal in these research projects is to elucidate the underlying fundamental chemistry and engineering principles and to use that insight to direct our creative and scientific efforts. In one of their current research projects, they are designing, synthesizing, and characterizing novel dendrimers, termed “biodendrimers,” for tissue engineering and biotechnological applications. Currently, they are evaluating these novel biomaterials for the repair of corneal lacerations, for the delivery of anti-cancer drugs, for the delivery of DNA, and as temporary biodegradable scaffolds for cartilage repair. In a second project, they are creating novel polymeric coatings termed “interfacial biomaterials” that control biology on plastic, metal, and ceramic surfaces. In a third project, they are designing new polymeric films and nanoparticles loaded with anticancer drugs for the prevention of recurrent cancer after surgical resection.

Mark is a co-founder of several companies that are commercializing his ideas, and he has several products being sold and used in the clinic.

Other Positions

  • Director, Nanotechnology Innovation Center (BUnano), Boston University
  • Professor, Biomedical Engineering, Boston University College of Engineering
  • Professor, Pulmonary, Allergy, Sleep & Critical Care Medicine, Medicine, Boston University School of Medicine


  • University of Illinois, PhD
  • Occidental College, AB


  • Published on 9/11/2018

    Herrera VL, Colby AH, Ruiz-Opazo N, Coleman DG, Grinstaff MW. Nucleic acid nanomedicines in Phase II/III clinical trials: translation of nucleic acid therapies for reprogramming cells. Nanomedicine (Lond). 2018 Aug; 13(16):2083-2098. PMID: 30204054.

    Read at: PubMed
  • Published on 8/7/2018

    Wathier M, Lakin BA, Cooper BG, Bansal PN, Bendele AM, Entezari V, Suzuki H, Snyder BD, Grinstaff MW. A synthetic polymeric biolubricant imparts chondroprotection in a rat meniscal tear model. Biomaterials. 2018 Nov; 182:13-20. PMID: 30099277.

    Read at: PubMed
  • Published on 7/26/2018

    Cooper BG, Catalina Bordeianu, Nazarian A, Snyder BD, Grinstaff MW. Active agents, biomaterials, and technologies to improve biolubrication and strengthen soft tissues. Biomaterials. 2018 Oct; 181:210-226. PMID: 30092370.

    Read at: PubMed
  • Published on 7/18/2018

    Reynolds DS, Bougher KM, Letendre JH, Fitzgerald SF, Gisladottir UO, Grinstaff MW, Zaman MH. Mechanical confinement via a PEG/Collagen interpenetrating network inhibits behavior characteristic of malignant cells in the triple negative breast cancer cell line MDA.MB.231. Acta Biomater. 2018 Sep 01; 77:85-95. PMID: 30030173.

    Read at: PubMed
  • Published on 5/29/2018

    Chapman Varela J, Sankar K, Hino A, Lin X, Chang WS, Coker D, Grinstaff M. Piperidinium ionic liquids as electrolyte solvents for sustained high temperature supercapacitor operation. Chem Commun (Camb). 2018 May 29; 54(44):5590-5593. PMID: 29766179.

    Read at: PubMed
  • Published on 5/10/2018

    Ekladious I, Liu R, Varongchayakul N, Mejia Cruz LA, Todd DA, Zhang H, Oberlies NH, Padera RF, Colson YL, Grinstaff MW. Reinforcement of polymeric nanoassemblies for ultra-high drug loadings, modulation of stiffness and release kinetics, and sustained therapeutic efficacy. Nanoscale. 2018 May 10; 10(18):8360-8366. PMID: 29717728.

    Read at: PubMed
  • Published on 4/18/2018

    Christadore L, Grinstaff MW, Schaus SE. Fluorescent Dendritic Micro-Hydrogels: Synthesis, Analysis and Use in Single-Cell Detection. Molecules. 2018 Apr 18; 23(4). PMID: 29669998.

    Read at: PubMed
  • Published on 4/17/2018

    Nickmanesh R, Stewart RC, Snyder BD, Grinstaff MW, Masri BA, Wilson DR. Contrast-enhanced computed tomography (CECT) attenuation is associated with stiffness of intact knee cartilage. J Orthop Res. 2018 Apr 17. PMID: 29667235.

    Read at: PubMed
  • Published on 4/13/2018

    Bhattarai A, Honkanen JTJ, Myller KAH, Prakash M, Korhonen M, Saukko AEA, Virén T, Joukainen A, Patwa AN, Kröger H, Grinstaff MW, Jurvelin JS, Töyräs J. Quantitative Dual Contrast CT Technique for Evaluation of Articular Cartilage Properties. Ann Biomed Eng. 2018 Jul; 46(7):1038-1046. PMID: 29654384.

    Read at: PubMed
  • Published on 2/27/2018

    Nelson BB, Kawcak CE, Barrett MF, McIlwraith CW, Grinstaff MW, Goodrich LR. Recent advances in articular cartilage evaluation using computed tomography and magnetic resonance imaging. Equine Vet J. 2018 Sep; 50(5):564-579. PMID: 29344988.

    Read at: PubMed

View 261 more publications: View full profile at BUMC

View all profiles